9.02
price down icon4.55%   -0.43
after-market 시간 외 거래: 9.02
loading
전일 마감가:
$9.45
열려 있는:
$10.17
하루 거래량:
9,692
Relative Volume:
1.38
시가총액:
$N/A
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-33.63%
1개월 성능:
-2.70%
6개월 성능:
-1.42%
1년 성능:
+0.00%
1일 변동 폭
Value
$9.02
$10.29
1주일 범위
Value
$9.02
$14.80
52주 변동 폭
Value
$2.60
$16.75

Newamsterdam Pharma Company N V Stock (NAMSW) Company Profile

Name
명칭
Newamsterdam Pharma Company N V
Name
전화
31 35 206 2971
Name
주소
Gooimeer 2-35, Naarden
Name
직원
22
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
NAMSW's Discussions on Twitter

NAMSW을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
NAMSW 9.02 0 0 0 0 0.00
VRTX 450.37 115.10B 10.63B -479.80M -1.35B 13.33
REGN 744.50 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 596.74 35.07B 1.86B -40.29M -1.28B -4.16
ALNY 246.80 32.20B 2.09B -332.26M 16.06M -4.14
BNTX 108.23 25.09B 3.30B -501.07M 1.03B 11.54

Newamsterdam Pharma Company N V 주식(NAMSW)의 최신 뉴스

pulisher
08:22 AM

NewAmsterdam Pharma's (NAMS) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat

08:22 AM
pulisher
Nov 20, 2024

NewAmsterdam Pharma target raised to $45 on strong trial data - Investing.com

Nov 20, 2024
pulisher
Nov 20, 2024

Newamsterdam’s obicetrapib combo nails phase III LDL-C endpoints - BioWorld Online

Nov 20, 2024
pulisher
Nov 20, 2024

NewAmsterdam Pharma target raised to $45 on strong trial data By Investing.com - Investing.com UK

Nov 20, 2024
pulisher
Nov 20, 2024

NewAmsterdam Pharma stock falls on trial data (NAMS:NASDAQ) - Seeking Alpha

Nov 20, 2024
pulisher
Nov 20, 2024

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH - The Manila Times

Nov 20, 2024
pulisher
Nov 19, 2024

NewAmsterdam Pharma stock holds Overweight rating with catalysts ahead in Ph3 topline readouts - Investing.com

Nov 19, 2024
pulisher
Nov 19, 2024

Trend Tracker for (NAMSW) - Stock Traders Daily

Nov 19, 2024
pulisher
Nov 19, 2024

Frazier Life Sciences Bolsters Leadership with Two Senior Industry Veterans | NAMS Stock News - StockTitan

Nov 19, 2024
pulisher
Nov 18, 2024

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 - The Manila Times

Nov 18, 2024
pulisher
Nov 15, 2024

RA Capital Management, L.P. Expands Stake in NewAmsterdam Pharma Co NV - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

GSA Capital Partners LLP Has $1.10 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) surges 13%; private equity firms who own 46% shares profited along with institutions - Simply Wall St

Nov 14, 2024
pulisher
Nov 13, 2024

When the Price of (NAMS) Talks, People Listen - Stock Traders Daily

Nov 13, 2024
pulisher
Nov 13, 2024

Is NewAmsterdam Pharma (NAMS) Top Performing European Stock Heading into 2025? - Insider Monkey

Nov 13, 2024
pulisher
Nov 12, 2024

10 Top Performing European Stocks Heading into 2025 - Insider Monkey

Nov 12, 2024
pulisher
Nov 12, 2024

Lisanti Capital Growth LLC Invests $700,000 in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Nov 12, 2024
pulisher
Nov 11, 2024

NewAmsterdam Pharma Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga

Nov 11, 2024
pulisher
Nov 11, 2024

Q4 EPS Forecast for NewAmsterdam Pharma Reduced by Analyst - Defense World

Nov 11, 2024
pulisher
Nov 11, 2024

William Blair Issues Pessimistic Forecast for NAMS Earnings - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Leerink Partnrs Has Bullish Outlook for NAMS FY2024 Earnings - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Equities Analysts Offer Predictions for NAMS FY2024 Earnings - Defense World

Nov 11, 2024
pulisher
Nov 10, 2024

Leerink Partnrs Has Strong Estimate for NAMS FY2028 Earnings - Defense World

Nov 10, 2024
pulisher
Nov 09, 2024

Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $33.80 - Defense World

Nov 09, 2024
pulisher
Nov 08, 2024

(NAMSW) Proactive Strategies - Stock Traders Daily

Nov 08, 2024
pulisher
Nov 08, 2024

What is Leerink Partnrs' Forecast for NAMS FY2028 Earnings? - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

NewAmsterdam Pharma Reports Strong Q3 and Trial Progress - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Buy" Rating from Needham & Company LLC - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

What 4 Analyst Ratings Have To Say About NewAmsterdam Pharma - Benzinga

Nov 07, 2024
pulisher
Nov 07, 2024

Newamsterdam Pharma Faces Compliance Cost Surge as Emerging Growth Status Ends - TipRanks

Nov 07, 2024
pulisher
Nov 06, 2024

NewAmsterdam Pharma (NASDAQ:NAMS) Receives $33.80 Consensus PT from Analysts - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

NewAmsterdam Pharma Revenue Soars 900%, Reports Strong Q3 Results Ahead of Key Trial Data | NAMS Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 05, 2024

abrdn plc Purchases 53,060 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Nov 05, 2024
pulisher
Nov 03, 2024

(NAMS) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 03, 2024
pulisher
Nov 01, 2024

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 01, 2024
pulisher
Oct 29, 2024

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November - The Manila Times

Oct 29, 2024
pulisher
Oct 25, 2024

Needham Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy Recommendation - MSN

Oct 25, 2024
pulisher
Oct 18, 2024

NewAmsterdam Pharma to Restate Prior Financials By Investing.com - Investing.com Australia

Oct 18, 2024
pulisher
Oct 18, 2024

NewAmsterdam Pharma to Restate Prior Financials - Investing.com India

Oct 18, 2024
pulisher
Oct 18, 2024

Latest Company News - Investing.com UK

Oct 18, 2024
pulisher
Oct 17, 2024

(NAMSW) Trading Report - Stock Traders Daily

Oct 17, 2024
pulisher
Oct 14, 2024

NewAmsterdam Pharma Breaks Above 200-Day Moving AverageBullish for NAMS - Nasdaq

Oct 14, 2024
pulisher
Oct 12, 2024

Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) Target Price at $33.80 - MarketBeat

Oct 12, 2024
pulisher
Oct 11, 2024

NewAmsterdam Pharma Company N.V. (NAMS) Price Target Increased by 8.93% to 31.11 - MSN

Oct 11, 2024
pulisher
Oct 11, 2024

Marshall Wace LLP Decreases Stake in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Oct 11, 2024
pulisher
Oct 07, 2024

When the Price of (NAMSW) Talks, People Listen - Stock Traders Daily

Oct 07, 2024
pulisher
Oct 05, 2024

Millennium Management LLC Has $22.39 Million Stock Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Oct 05, 2024
pulisher
Oct 04, 2024

Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies - Seeking Alpha

Oct 04, 2024
pulisher
Oct 01, 2024

NewAmsterdam Pharma executive sells shares worth $707,400 By Investing.com - Investing.com South Africa

Oct 01, 2024
pulisher
Oct 01, 2024

NewAmsterdam Pharma executive sells shares worth $707,400 - Investing.com India

Oct 01, 2024
pulisher
Oct 01, 2024

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down to $16.60 - MarketBeat

Oct 01, 2024

Newamsterdam Pharma Company N V (NAMSW) 재무 분석

Newamsterdam Pharma Company N V (NAMSW)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.55%
$367.36
price up icon 0.83%
$194.56
price up icon 0.15%
$108.23
price up icon 5.96%
자본화:     |  볼륨(24시간):